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The Third Beta Is Not the Charm
 
Editorial
 
In this issue of 
 
The Journal
 
, Gauthier and colleagues provide
evidence for the presence of a third 
 
b
 
-adrenoceptor subtype,
the 
 
b
 
3
 
-adrenoceptor, in human heart. However, unlike 
 
b
 
1
 
- or
 
b
 
2
 
-adrenoceptors, the 
 
b
 
3
 
-adrenoceptor functions to inhibit
cardiac contractility (1). The authors state that “this unex-
pected finding could interfere with the pathogenesis of car-
diac failure, during which modification of 
 
b
 
1
 
- and 
 
b
 
2
 
-adre-
noceptor occurs” (1).
In heart failure, there is an increase in circulating and re-
leased epinephrine and norepinephrine in an attempt to stimu-
late contractility through 
 
b
 
1
 
- and 
 
b
 
2
 
-adrenoceptor activation.
While this presence of excess stimulation may initially improve
cardiac function, the long-term consequences are diminished
contractility of the myocardium through desensitization and a
subsequent loss of 
 
b
 
-adrenoceptors (primarily of the 
 
b
 
1
 
-sub-
type) (2). Thus, activation of the inhibitory 
 
b
 
3
 
-adrenoceptors
described by Gauthier et al. could produce further decreases in
contractility and possible exacerbation of the clinical symp-
toms associated with heart failure. There are three factors
which make this a plausible conclusion. First, the 
 
b
 
3
 
-adreno-
ceptor has been demonstrated to be relatively resistant to
chronic, agonist-induced desensitization processes since it
lacks the relevant sites for phosphorylation by G protein–cou-
pled receptor kinases (3). Therefore, it may play an important
role in the presence of diminished numbers of 
 
b
 
1
 
-adrenocep-
tors. Second, norepinephrine, the primary neurotransmitter
released by the sympathetic innervation to the heart, has rela-
tively high affinity for the 
 
b
 
3
 
-adrenoceptor, unlike the 
 
b
 
2
 
-sub-
type. Also, studies of the 
 
b
 
3
 
-adrenoceptor in certain tissues
have shown responses to sympathetic nerve stimulation sug-
gesting a postjunctional localization in at least some tissues.
Third, there is evidence to suggest that G
 
i
 
, the G protein impli-
cated in the 
 
b
 
3
 
-adrenoceptor signaling in human ventricle, may
be upregulated in certain types of heart failure (4). An in-
crease in the amount of available G protein may produce in-
creases in cellular responses, even at the same level of receptor
activation. That an increase in G
 
i
 
 protein levels is responsible
for the “promiscuous coupling” of the 
 
b
 
3
 
-adrenoceptor in this
report is unlikely because the studies were performed on tissue
samples from the donor hearts, not the hearts removed due to
failure.
At a basic research level, the report by Gauthier et al. is in-
triguing because, to our knowledge, it is the first report impli-
cating a 
 
b
 
-adrenoceptor whose primary biochemical function
appears to be inhibitory. Most reports in native systems have
described 
 
b
 
-adrenoceptors as coupling quite faithfully to their
preferred second messenger G protein, G
 
s
 
,
 
 
 
resulting in activa-
tion of adenylate cyclase. Indeed, there is pharmacological evi-
dence for the existence of a stimulatory 
 
b
 
3
 
-adrenoceptor in hu-
man atrium (5). Inhibitory pertussis toxin–sensitive responses
to 
 
b
 
2
 
- and 
 
b
 
3
 
-adrenoceptor stimulation have been reported,
but these responses were attenuation of the primary response
of increasing adenylate cyclase (6, 7). Thus, the net response of
receptor activation was still an increase in adenylate cyclase
activity. The results obtained by Gauthier et al. show that
whether as a result of coupling to a single inhibitory G protein,
or to multiple signaling pathways, the net effect of 
 
b
 
3
 
-adreno-
ceptor activation is inhibition of ventricular myocardial con-
tractility (1). The results also stress the dangers of screening
for a receptor based on presumed second messenger function.
For example, it is likely that assaying for increases in adenylate
cyclase activity would not have revealed a functional 
 
b
 
3
 
-adre-
noceptor in human heart.
To summarize, the existence of functional 
 
b
 
3
 
-adrenocep-
tors in human myocardium which inhibit contractility adds an-
other dimension to the current framework of how disordered
adrenergic regulation of the heart may contribute to the patho-
genesis of cardiac failure. At a time when marked increases in
sympathetic tone and cardiac norepinephrine release have
rendered the inotropic 
 
b
 
1
 
-adrenoceptor system relatively unre-
sponsive, the desensitization-resistant 
 
b
 
3
 
-adrenoceptors would
presumably continue to mediate a negative inotropic effect via
an interaction with an upregulated pool of G
 
i 
 
proteins. If these
mechanisms do in fact operate as the heart fails, then one
might speculate that drugs which block 
 
b
 
3
 
-adrenoceptors
might be of therapeutic benefit in such circumstances. This
conjecture is even more provocative in the light of recent find-
ings that certain 
 
b
 
-adrenoceptor antagonists are of therapeutic
value in the treatment of chronic congestive heart failure (8).
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